“Metastatic colorectal cancer remains a formidable challenge with limited effective therapies. The promising early results with petosemtamab offer hope for advancing care and bringing new treatment ...

Merck, a leading science and technology company, will present data at the ESMO 18 th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, ...

Mental Disorders Among Adolescents and Young Adults With Cancer: A Canadian Population–Based and Sibling Cohort Study A combination of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is the ...

Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with standard of care ...

Petosemtamab plus FOLFOX: Most frequent treatment-emergent adverse events (TEAEs) regardless of causality (all Grades [G]/G3) were dermatitis acneiform (71%/0%), constipation (43%/0%), fatigue (43%/0% ...

Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...

Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer Three thousand sixty-one cases had tumor samples, of which 2,643 ...

Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is currently conducting a Phase 1 clinical study titled A ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...